Intrexon reported $23.02M in Current Liabilities for its fiscal quarter ending in June of 2024.





Current Liabilities Change Date
Agenus USD 231.82M 17.42M Jun/2026
Alaunos Therapeutics USD 864K 269K Jun/2026
Amgen USD 23.23B 2.27B Sep/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 311.34M 27.99M Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Heron Therapeutics USD 89.85M 2.3M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Intrexon USD 23.02M 38K Jun/2024
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Ligand Pharmaceuticals USD 500.57M 453.83M Sep/2026
MacroGenics USD 107.23M 1.58M Sep/2026
MannKind USD 108.52M 34.37M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Novartis USD 32.52B 777M Sep/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Thermo Fisher Scientific USD 14.17B 899M Sep/2026
Veracyte USD 84.21M 21.47M Sep/2026
Xencor USD 76.27M 5.6M Sep/2026